The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and
imipenem in hospitalised subjects with complicated skin and skin structure infections.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca Pfizer
Treatments:
Cilastatin Cilastatin, Imipenem Drug Combination Imipenem Meropenem Thienamycins